• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens. All the platforms and services are label free with no modification of the original molecules.

    Understand the mode of action of your compound

    Identify and validate drug-target engagement

    Lead compound optimization

    Patient stratification and biomarkers discovery

    Indication prioritization

    Identify biomarkers and clinical pharmacology

    SPR services 

    MoA Screening

  • Technology

    Technology

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    Preclinical

    How to best identify the Mode of Action of your compound

    Read more

    From preclinical to clinical

    Ensure Phase II study and success of your drug candidate in Phase III

    Read more

    Clinical

    Successfully identify the cohort of patients who will respond to your therapy

    Read more

  • Expertise

    Our expertise in translational pharmacology

    Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

    Translational pharmacology expertise

    Pre-clinical to clinical phases

    Read more

    Our innovative approach

    Biomarkers, patient and therapeutic window

    Read more

    Advantages of approach

    Save time and money

    Read more

    How we work with clients

    Tailored methodologies and technologies 

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us

Our team

Dr. Pierre EFTEKHARI

President & Chief Scientific Officer (CSO)

Linkedin Envelope

Dr Eftekhari is a life sciences entrepreneur with extensive world-class knowledge in drug development. He has more than fifteen years combined academic and industrial experience in pharmacology. His considerable experience in the drug development process has equipped him to develop state-of-the-art technologies.

Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he has built with pharmaceutical companies and academic laboratories at the international level have given him an in-depth understanding of the pharmaceutical industry’s needs.

He holds a PhD in biology, with a major in pharmacology, from the Louis Pasteur University, Strasbourg.

Our team

Alessandro BONA

Head of External R&D Innovation Manager

Linkedin

Dr. Angélique QUARTIER

Head of Molecular Biology

Linkedin

Scientific Board

Dr. Johan HOEBEKE

Retired CNRS Research Director

Linkedin

Dr. Johan Hoebeke has more than 250 publications to his name in peer-reviewed international journals, as well as eight patents. His research interests focus on physical chemistry as applied to molecular immunology and molecular pharmacology. Recently retired from his position as CNRS Research Director in the Department of Immunological and Chemical Therapeutics at the Institute of Molecular and Cell Biology at the University of Strasbourg (France), Dr. Hoebeke began his career teaching at the University of Kinshasa, Democratic Republic of the Congo. Later, he joined the research laboratories at Janssen Pharmaceutical in Belgium. On his return to academic research, he worked as Senior Scientist in the Pathological Biochemistry Department of the Free University of Brussels, Belgium. He also worked at the Jacques Monod Institute in Paris and then at the François Rabelais University in Tours. He spent a sabbatical period in the Wallenberg Laboratories at the University of Gothenburg, Sweden.

Dr. Hoebeke graduated with a BSc (1959) and PhD (1965) in biochemistry from the Catholic University of Leuven, Belgium.

Professor Jörg WISCHHUSEN

Head of the Experimental Tumor Immunology Department of Würzburg University’s Medical School

Linkedin

Since 2013, Prof. Wishchusen has served as Head of the Experimental Tumor Immunology Department of Würzburg University’s Medical School. Currently, his research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance. Strategies to relieve local suppression of NK and T cell effector functions by cytokines and other soluble factors are being investigated for their potential therapeutic use. Prof. Wischhusen trained as a biochemist at the University of Tübingen. After graduating in the field of molecular neuro-oncology, he became Research Group Leader at the Interdisciplinary Centre for Clinical Research in Würzburg, where he focused on mechanisms of tumor progression and immune escape.

Dr. Matthias BREIDERT

Head of the Dept. of Gastroenterology (Kantonsspital Olten, Switzerland)

Matthias Breidert, MD, assistant Professor at the Technical University of Munich, was born in 1963 in Darmstadt, Germany. Currently, head of the Dept. of Gastroenterology (Kantonsspital Olten, Switzerland). Dr. Breidert is vicepresident of the Gastroenterology Foundation e.v. (München) since 2013: support of University Hospitals for Interventional Gastroenterological Endoscopy in Nepal (Dhulikel Hospital, University Kathmandu) since 2009, Tanzania (Muhimbili Hospital, University, Daressalam) since 2010, Pristina (Kosovo) since 2019 and Bishkek (Kyrgyzstan) since 2022.

He is part of some Scientific members such as German Society of Gastroenterology and Metabolism (DGVS), Swiss Society of Gastroenterology (SGG), German Society of Endoscopy (DGE-BV),
Swiss Society for Ultrasound (SGUM, Board of Directors). 

Dr. Breidert has written more than 100 papers in peer-reviewed journals and in reviews in the field of Gastrointestinal Diseases, Endoscopy, Hepatology and Endocrinology/Diabetology, and he is main reviewer of IWQIG (The independent Institute for Quality and Efficiency in Health Care) since 2012 for Gastroenterology and Endocrinology.

Supervisory Board & Investors

Dr. Pierre EFTEKHARI

President & Chief Scientific Officer (CSO)

Linkedin Envelope

Dr Eftekhari is a life sciences entrepreneur with extensive world-class knowledge in drug development. He has more than fifteen years combined academic and industrial experience in pharmacology. His considerable experience in the drug development process has equipped him to develop state-of-the-art technologies.

Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he has built with pharmaceutical companies and academic laboratories at the international level have given him an in-depth understanding of the pharmaceutical industry’s needs.

He holds a PhD in biology, with a major in pharmacology, from the Louis Pasteur University, Strasbourg.

Léone ATAYI

Chief Financial Officer (CFO)

Linkedin Envelope

Leone has been patiently involved in structuring and building up innovative companies for the passed 15 years. She has put her academic knowledge in human resource management and her practical experiences in finance and strategy making at the service of multiple companies. Before joining Inoviem scientific Leone has been working with Polyplus transfection where she acted as CFO.

Léone ATAYI

Jean-Paul ANSEL

Board Member

Linkedin

Jean-Paul has more than 45 years of international banking and financing experience. His academic knowledge is rooted in Paris business school (ESCP) that allows him to grow his highly riche international experience through  Scoa, Davum, MITSUI, Bank worms group, The Chase Manhattan bank N.A, Merill Lynch, HSBC Investment Bank, Commerzbank securities and Pennel Industries.

Jean-Paul is leading DMS group where his expertise has blossomed through acquirement of  several companies all highly focused on human health, particularly personalized medicine. 

Headquarter
Bioparc 2, 850 boulevard Sébastien Brant,
67400 Illkirch-Graffenstaden

CONTACT US


SERVICES
EXPERTISE

Our expertise in translational pharmacology
Advantages of a translational pharmacology approach
How we work with clients

TECHNOLOGY

Preclinical
From preclinical to clinical
Clinical

RESOURCES
ABOUT US

Our mission
Our team

PRIVACY POLICY
Need Help